Atara Biotherapeutics Inc. (NASDAQ:ATRA) rose 7.2% during trading on Monday . The stock traded as high as $22.83 and last traded at $22.75, with a volume of 61,960 shares trading hands. The stock had previously closed at $21.22.

A number of research analysts recently weighed in on the company. Jefferies Group reaffirmed a “buy” rating and set a $22.00 price target (down from $26.00) on shares of Atara Biotherapeutics in a research note on Monday, May 9th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 10th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $27.71.

The company has a 50 day moving average of $22.74 and a 200 day moving average of $19.32. The company’s market capitalization is $643.93 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, analysts predict that Atara Biotherapeutics Inc. will post ($2.75) EPS for the current year.

In related news, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $20.53, for a total value of $246,360.00. Following the sale, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at $4,582,870.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $22.11, for a total value of $212,256.00. Following the completion of the sale, the chief executive officer now directly owns 223,228 shares in the company, valued at $4,935,571.08. The disclosure for this sale can be found here.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.